Dear John,

ICYMI, Dr. Jay Bhatt, Managing Director of the Deloitte Center for Health Solutions and the Deloitte Health Equity Institute, appeared on A Health Podyssey to discuss the role that Deloitte has played in pursuing health equity goals across the life sciences and health care industry.

The first weekend of autumn has arrived and it's time for us to take a second to check out what's been happening in the world of health policy.

After pushback from providers and the federal government, it was reported that Johnson & Johnson would be dropping a plan where the company would pay hospitals after-the-fact rebates for two widely prescribed medications in the 340B Drug Discount Program, as opposed to at the point of sale.

Let's take a moment to see what Health Affairs has published on the 340B program over the years.

Access To Oncology Services In Rural Areas: Influence Of The 340B Drug Pricing Program

Kelsey M. Owsley and Cathy J. Bradley (June 2023)

The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program

Amelia M. Bond et al. (May 2023)

The 340B Discount Program: Outpatient Prescription Dispensing Patterns Through Contract Pharmacies In 2012

Bobby L. Clark et al. (November 2014)

The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities

Rena M. Conti and Peter B. Bach (October 2014)

Protecting Federally Qualified Health Centers Amid Drugstore Closures And Threats To 340B

Callie A. Gu et al. (July 2024)

340B: Good Intentions In Need Of Reform

Anthony M. DiGiorgio (February 2023)

Proposed Reforms To The 340B Drug Discount Program

Rena M. Conti et al. (March 2018)

Kelsey Owsley on 340B's Effect on Oncology Services (June 2023)

Amelia Bond on 340B's Influence on Biosimilars (May 2023)

The 340B Drug Discount Program

Mike McCaughan (September 2017)

Published Today

Rachel Sachs Explains the FTC's Pharmacy Benefit Manager Lawsuit & PBM Reform

Health Affairs' Jeff Byers is joined by Deputy Editor Chris Fleming and Rachel Sachs of Washington University, St. Louis to discuss a recent lawsuit filed by the Federal Trade Commission (FTC) against the three largest pharmacy benefit managers (PBMs) in the country for rebating practices that the FTC claims resulted in inflating the list price of insulin.

Federal Court Rejects Challenge To Oregon’s Health Care Transaction Review Law

Emily Schneider and Sheela Ranganathan

part of our Provider Prices In The Commercial Sector series

Advancing Equity through Accountable Care with Purva Rawal from the CMS Innovation Center

Join Health Affairs Thursday, October 17, 2024, for a virtual event featuring a conversation between Health Affairs Senior Editor Margaret Winchester and Purva Rawal, the Chief Strategy Officer for the CMS Innovation Center, on advancing equity through accountable care.